



GENOOX AND MGI TECH JOIN FORCES TO ENHANCE PRECISION GENOMICS ACROSS ASIA PACIFIC

September 12, 2024

GENOOX INC

California Ave, Palo Alto, CA 94306, USA 550

Phone: +1 (877) 408 9188 Email : info@genoox.com | www.genoox.com

Genoox and MGI Tech Join Forces to Enhance Precision Genomics Across Asia Pacific

Release Date: September 12, 2024

Writer: Genoox

Palo Alto, California, September 12, 2024 - Genoox, a pioneering platform in genomic data interpretation and analysis, today announced a strategic collaboration with MGI (MGI Tech Co., Ltd. or its subsidiaries, collectively referred to as MGI), a company committed to building core tools and technologies that drive innovation in life science. The agreement, signed during the 2024 Future of Omics Conference in Shenzhen, marks a significant step towards advancing genomics solutions in the Asia Pacific region.

This partnership aims to co-market and demonstrate the compatibility of MGI's cutting-edge sequencing platforms, including DNBSEQ-G99, DNBSEQ-G400, DNBSEQ-T7, and the modular sequencing workstation MGIFLP-L50, with Genoox's industry-leading Franklin platform. The collaboration will enable both companies to jointly develop and promote integrated solutions, further enhancing their offerings to customers across the Asia Pacific region.

"We are thrilled to partner with MGI, a company that shares our vision of improving patient care by making genomic data actionable. This collaboration is a key component of Genoox's global expansion strategy, particularly in expanding our presence in developed countries across the Asia Pacific region. The synergy between Genoox's advanced data interpretation platform and MGI's state-of-the-art sequencing machines holds tremendous potential for revolutionizing the way genomic data is analyzed and utilized. With MGI being a dominant player in these areas, this partnership will enable customers to benefit from highly reliable and accurate tools for secondary and tertiary analysis, allowing researchers and clinicians to derive more actionable insights from genomic data," said Amir Trabelsi, CEO of Genoox.

"Our partnership with Genoox is a significant achievement in our mission to offer innovative sequencing solutions that meet the changing needs of the genomics



community,” said Duncan Yu, President of MGI. “By integrating MGI's advanced sequencing technology with Genoox's Franklin platform – a world-leading, connected, community-driven genetic interpretation and analysis solution, we are introducing our customers to a high-quality, end-to-end solution from sample to report. Together, we are creating a robust and seamless experience that will empower our customers with the most comprehensive tools available, enabling them to achieve groundbreaking discoveries.”

The partnership includes a comprehensive Co-Marketing Plan, under which both parties will jointly validate selected workflows using MGI's StandardMPS 2.0 sequencing chemistry and explore new applications for validation and mutual co-marketing activities in the Asia Pacific territories. Both companies will collaborate on developing training programs, creating marketing materials, and participating in events to promote their combined solutions.

About Genoox

Founded in 2014, Genoox is a genomic analysis company utilizing a sophisticated AI engine with machine-learning algorithms to analyze genetic mutations, making clinical genetic sequencing more accessible and affordable. By streamlining the process, Genoox reduces the costs associated with detecting the connection between genetic mutations and medical conditions. The Genoox platform also facilitates the secure sharing of complex clinical data among researchers, clinicians, and medical facilities. Genoox is headquartered in Palo Alto, CA with offices in Tel Aviv, Israel.

For additional information about Genoox, visit our website at www.genoox.com. Stay connected with us on [LinkedIn](#) and [Twitter](#), or contact our team directly at Marketing@genoox.com.

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With



unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit the MGI [website](#) or connect with us on [Twitter](#), [LinkedIn](#) or [YouTube](#).